Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
Retrieved on:
Tuesday, April 16, 2024
Melanoma Research, Cancer, CMO, HKEX, Rutgers University, Learning, Biochemistry, Hospital, Mentorship, Oncology, Research, Hematology, IIC, Tufts Medical Center, Partnership, Pharmaceutical industry, NF-1, Molecular biology, Melanoma, Environment, Certification, Science, GSK, Patient, TMB, Faculty, Harvard Medical School, Pembrolizumab, Drug development, Merck, Massachusetts General Hospital, Autoimmunity, SAN, Dana–Farber Cancer Institute
Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program.
Key Points:
- Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program.
- Dr. Nageatte Ibrahim has over 11 years of oncology industry drug development experience at Merck and GSK.
- Dr. Ibrahim possesses a Pennsylvania Medical License and ABIM Certification in Medical Oncology.
- "We are very excited to welcome Dr. Nageatte Ibrahim onboard as our Oncology CMO in Global Clinical Development," said Dr. Michael Yu, Founder, Chairman and CEO of Innovent.